Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Karus Therapeutics Appoints Penelope Ward as CMO

Published: Tuesday, November 12, 2013
Last Updated: Tuesday, November 12, 2013
Bookmark and Share
Dr Ward will drive Company’s HDAC6 and PI3K inhibitor programmes.

Karus Therapeutics has announced that Penelope Ward has joined the Company in the role of Chief Medical Officer.

Her appointment strengthens the Company’s expansion which recently saw the formation of a Scientific Advisory Board, appointment of additional R&D personnel and a move to a world-class biotech hub near Oxford.

Dr Ward, who took up her new position in October, is an experienced pharmaceutical physician with previous senior management roles at Pharmacia and Upjohn (Pfizer), UCB and Roche, and was previously Chief Medical Officer of Novimmune SA.

Her expertise in designing and implementing clinical development strategies will be important for the role at Karus where she will take responsibility for driving the Company’s HDAC6 and PI3K inhibitor programmes through early human efficacy trials in inflammation and cancer.

In addition, Dr Ward brings with her broad capabilities in commercial licensing negotiations, having previously supported deals for novel research targets to full development candidates.

Along with a solid track record in obtaining regulatory approval, Dr Ward is well placed to assist the Company in future strategic decision making.

Commenting on Dr Ward’s appointment, Dr Simon Kerry, Chief Executive of Karus, said: “With the wealth of expertise that Penny brings to the position, we are confident she will be an asset to the team and look forward to working together to further develop and strengthen our proprietary programmes to treat inflammation and cancer.”

Dr Ward, Chief Medical Officer, added: “Karus is at a very exciting stage in its development, being well funded by supportive investors and with a great team. I look forward to working with the Board, management and scientists to progress the Company’s assets and realize the potential of its technology.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Karus Therapeutics Appoints Scientific Advisory Board
Company announces move to new Oxford facilities.
Tuesday, April 09, 2013
Karus Secures Series B Financing from a Syndicate of Leading VC Investors
New investment to support the development of Karus’s innovative PI3K and HDAC6 programmes through early human trials.
Thursday, January 17, 2013
Karus Therapeutics Announces Collaboration with Babraham Institute
Collaboration to explore PI3 kinase inhibitors in the treatment of inflammatory diseases.
Tuesday, December 18, 2012
Karus Commences Preclinical Development of Novel Immune and Inflammation Programmes
The Company aims to initiate clinical trials for both programmes in 2011.
Wednesday, November 03, 2010
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
A Peachy Defense System for Seeds
ETH chemists are developing a new coating method to protect seeds from being eaten by insects. In doing so, they have drawn inspiration from the humble peach and a few of its peers.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!